Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Concin

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2025
The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexityEmilia Palmieri, Andrea Mariani, Robert Coleman, et al.
Gynecologic Oncology|February 18, 2022
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancerAdriaan Vanderstichele, Liselore Loverix, Pieter Busschaert, et al.
Oncology Research and Treatment|September 13, 2021
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse EventsPatrick Schöffski, Nicole Concin, Cristina Suarez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 12, 2024
Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) projectTanja Nikolova, Esra Bilir, Nicolò Bizzarri, et al.
Cancer|January 30, 2002
The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter studyLukas A Hefler, Nicole Concin, David Mincham, et al.
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivoNicole Concin, Gerda Hofstetter, Astrid Berger, et al.
Journal of Ovarian Research|July 2, 2013
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortiumFabian Trillsch, Linn Woelber, Christine Eulenburg, et al.
Oncology Reports|December 3, 2011
MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancerGerda Hofstetter, Astrid Berger, Eva-Maria Bauer, et al.
Cancer Research|April 15, 2010
Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancerAlexander M Strasak, Georg Goebel, Hans Concin, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2025
The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexityEmilia Palmieri, Andrea Mariani, Robert Coleman, et al.
Gynecologic Oncology|February 18, 2022
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancerAdriaan Vanderstichele, Liselore Loverix, Pieter Busschaert, et al.
Oncology Research and Treatment|September 13, 2021
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse EventsPatrick Schöffski, Nicole Concin, Cristina Suarez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 12, 2024
Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) projectTanja Nikolova, Esra Bilir, Nicolò Bizzarri, et al.
Cancer|January 30, 2002
The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter studyLukas A Hefler, Nicole Concin, David Mincham, et al.
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivoNicole Concin, Gerda Hofstetter, Astrid Berger, et al.
Journal of Ovarian Research|July 2, 2013
Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortiumFabian Trillsch, Linn Woelber, Christine Eulenburg, et al.
Oncology Reports|December 3, 2011
MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancerGerda Hofstetter, Astrid Berger, Eva-Maria Bauer, et al.
Cancer Research|April 15, 2010
Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancerAlexander M Strasak, Georg Goebel, Hans Concin, et al.
Pageof 14